Sinopharm Tech Holdings Limited
Hong Kong Stock ExchangeTotal Valuation
Sinopharm Tech Holdings Limited carries a market capitalization of 128.64M, placing it among publicly traded companies globally. Its enterprise value stands at 19.53M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 128.64M |
| Enterprise Value | 19.53M |
Share Statistics
Sinopharm Tech Holdings Limited currently has 183.69M shares outstanding.
| Shares Outstanding | 183.69M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 0.52, and the price-to-book ratio stands at -0.01.
| PE Ratio | N/A |
| PS Ratio | 0.52 |
| PB Ratio | -0.01 |
| P/TBV Ratio | -0.13 |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
Enterprise Valuation
| EV / Sales | 0.42 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | 3.17 |
Financial Position
Sinopharm Tech Holdings Limited maintains a current ratio of 0.16, meaning it holds 0.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -5.48, indicating conservative leverage, while an interest coverage ratio of -1.75 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.16 |
| Quick Ratio | 0.04 |
| Debt / Equity | -5.48 |
| Debt / EBITDA | -0.88 |
| Interest Coverage | -1.75 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -57.54 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 9.65 |
Taxes
| Income Tax | -1.31M |
| Effective Tax Rate | N/A |
Stock Price Statistics
Sinopharm Tech Holdings Limited's stock has declined approximately -7.72727% over the past 52 weeks. The 50-day moving average sits at 0.24, while the 200-day moving average is 0.28.
| Beta (5Y) | N/A |
| 52-Week Price Change | -7.72727% |
| 50-Day Moving Average | 0.24 |
| 200-Day Moving Average | 0.28 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Sinopharm Tech Holdings Limited generated 46.66M in revenue and converted that into -28.92M in net income, yielding earnings per share of -0.15. EBITDA reached -11.32M, while operating income came in at -11.32M.
| Revenue | 46.66M |
| Gross Profit | 5.55M |
| Operating Income | -11.32M |
| Pretax Income | -29.41M |
| Net Income | -28.92M |
| EBITDA | -11.32M |
| EBIT | -11.32M |
| Earnings Per Share (EPS) | -0.15 |
Balance Sheet
Sinopharm Tech Holdings Limited holds 8.51M in cash and equivalents against 10.00M in total debt, resulting in a net debt position of 1.50M. Total book value stands at -2.92B, with working capital of -192.04M providing operational flexibility.
| Cash & Cash Equivalents | 8.51M |
| Total Debt | 10.00M |
| Net Debt | 1.50M |
| Equity (Book Value) | -2.92B |
| Book Value Per Share | -15.90 |
| Working Capital | -192.04M |
Margins
Sinopharm Tech Holdings Limited operates with a gross margin of 11.90, reflecting its pricing power and cost economics. The operating margin of -24.27 and net profit margin of -61.98 provide insight into operational efficiency.
| Gross Margin | 11.90 |
| Operating Margin | -24.27 |
| Pretax Margin | -63.04 |
| Profit Margin | -61.98 |
| EBITDA Margin | -24.27 |
Stock Splits
Sinopharm Tech Holdings Limited's most recent stock split took place on August 29, 2023 with a 25:1 split ratio.
| Last Split Date | 8/29/2023 |
| Split Ratio | 25:1 |
Scores
Sinopharm Tech Holdings Limited posts an Altman Z-Score of -102.23, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -102.23 |